Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER: UK API 22857 Insp GMP 22857/36790-0009

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER (1),(2)

Part 1

Issued following an inspection in accordance with:

Regulation 331A of The Human Medicines Regulations 2012 (SI 2012/1916)

The competent authority of United Kingdom confirms the following:

The Manufacturer: PHARMARON MANUFACTURING SERVICES (UK) LTD

Site address: PHARMARON MANUFACTURING SERVICES (UK) LTD, WINDMILL INDUSTRIAL ESTATE, SHOTTON LANE, CRAMLINGTON, NE23 3JL, UNITED KINGDOM

Is an active substance manufacturer that has been inspected in accordance with Regulation 327 of The Human Medicines Regulations 2012 (SI 2012/1916).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 24/03/2025, it is considered that it complies with

• The principles of GMP for active substances referred to in Regulation B17 and C17 of the Human Medicines Regulations 2012 (SI 2012/1916)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
- (2) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products

Manufacture of active substance. Names of substances subject to inspection:

- [1000000540] CANNABIDIOL
- [1000020451] ACOZIBOROLE
- [2000008238] NALOXONE HYDROCHLORIDE
- [3000017735] S-(+)-FLURBIPROFEN
- [1000000933] NITISINONE
- [4000007377] FLURBIPROFEN SODIUM DIHYDRATE

- [2000007755] DIPIPANONE HYDROCHLORIDE
- [1000000208] NALTREXONE
- [1000002036] FLURBIPROFEN

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

CANNABIDIOL

3.2 Processing Activities of Active Substance from Natural Sources

3.2.1 Plant Source Extraction

3.2.6 Purification of extracted substance

3.5 General Finishing Steps

3.5.1 Physical Processing Steps

Drying

3.5.2 Primary Packaging

3.5.3 Secondary Packaging

3.6 Quality Control Testing

3.6.1 Physical / Chemical testing

ACOZIBOROLE

3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.1 Manufacture Of Active Substance Intermediates

3.1.2 Manufacture Of Crude Active Substance

3.1.3 Salt Formation/Purification steps (eg. Crystallisation)

Crystallisation

3.5 General Finishing Steps

3.5.1 Physical Processing Steps

Filtration and drying

3.5.2 Primary Packaging

3.5.3 Secondary Packaging

3.6 Quality Control Testing

3.6.1 Physical / Chemical testing

NALOXONE HYDROCHLORIDE

3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.1 Manufacture Of Active Substance Intermediates

3.1.2 Manufacture Of Crude Active Substance

3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Salt formation and crystallisation 3.5 General Finishing Steps 3.5.1 Physical Processing Steps Drying 3.5.2 Primary Packaging 3.5.3 Secondary Packaging 3.6 **Quality Control Testing** 3.6.1 Physical / Chemical testing S-(+)-FLURBIPROFEN 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture Of Active Substance Intermediates 3.1.2 Manufacture Of Crude Active Substance 3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation General Finishing Steps 3.5 3.5.1 Physical Processing Steps Filtration, distillation, crystallisation and centrifugation 3.5.2 Primary Packaging 3.5.3 Secondary Packaging 3.6 **Quality Control Testing** 3.6.1 Physical / Chemical testing **NITISINONE** 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture Of Active Substance Intermediates 3.1.2 Manufacture Of Crude Active Substance 3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation General Finishing Steps 3.5 3.5.1 Physical Processing Steps Drying 3.5.2 Primary Packaging

3.5.3 Secondary Packaging

3.6 Quality Control Testing

3.6.1 Physical / Chemical testing

FLURBIPROFEN SODIUM DIHYDRATE

3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.1 Manufacture Of Active Substance Intermediates

3.1.3 Salt Formation/Purification steps (eg. Crystallisation)

Salt formation

3.5 General Finishing Steps

3.5.1 Physical Processing Steps

Dried in Oven

3.5.2 Primary Packaging

3.5.3 Secondary Packaging

3.6 Quality Control Testing

3.6.1 Physical / Chemical testing

DIPIPANONE HYDROCHLORIDE

3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.1 Manufacture Of Active Substance Intermediates

3.1.3 Salt Formation/Purification steps (eg. Crystallisation)

Crystallisation

3.5 General Finishing Steps

3.5.1 Physical Processing Steps

Drying

3.5.2 Primary Packaging

3.5.3 Secondary Packaging

3.6 Quality Control Testing

3.6.1 Physical / Chemical testing


NALTREXONE

3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.1 Manufacture Of Active Substance Intermediates

3.1.2 Manufacture Of Crude Active Substance

.6 Quality Control Testing



3.6.1 Physical / Chemical testing

FLURBIPROFEN

3.1 Manufacture of Active Substance by Chemical Synthesis

3.1.1 Manufacture Of Active Substance Intermediates

3.1.3 Salt Formation/Purification steps (eg. Crystallisation)

Sodium salt neutralised and subsequent base crystallised from petrol

3.5 General Finishing Steps

3.5.1 Physical Processing Steps

Dried on filter drier and passed through a mill system

3.5.2 Primary Packaging

3.5.3 Secondary Packaging

3.6 Quality Control Testing

3.6.1 Physical / Chemical testing

Restrictions or Remarks

This certificate is issued based on a desk-based assessment of GMP compliance information provided by the manufacturer. This certificate should be used in combination with the relevant authorisation/registration. A risk-based site inspection programme remains in force.

24/03/2025	Name and signature of the authorised person of the Competent Authority of United Kingdom
	Confidential
	Medicines and Healthcare products Regulatory Agency
	Tel: Confidential

